Dermata Therapeutics, Inc. (DRMA)
DRMA moved a median of -0.97% 30 minutes after news, and -2.37% by the close. How DRMA actually reacts to news — the realized, point-in-time move the market made, measured across 227 labeled events over the last three years with zero look-ahead.
DRMA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.36% | 37% | 210 |
| 30-min | -0.97% | 40% | 224 |
| 60-min | -0.70% | 35% | 225 |
| to close | -2.37% | 30% | 227 |
| Middle 50% of DRMA reactions | -2.93% to +1.59% |
|---|---|
| Median reaction (30-min) | -0.97% |
| Measured reactions | 227 |
Half of all Dermata Therapeutics, Inc. news events land between -2.93% and +1.59% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when DRMA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DRMA's baseline. Nothing else.
Recent DRMA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment | Press release | ACCESS Newswire | +18.06% | +18.07% | |
| Form S-3 Dermata Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | — | -12.78% | |
| Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment | Press release | ACCESS Newswire | -1.51% | +4.24% | |
| Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch | Press release | ACCESS Newswire | -0.21% | +2.90% | |
| Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | ACCESS Newswire | -2.41% | +0.69% | |
| Form 8-K Dermata Therapeutics, For: Aug 16 | SEC filing · Form 8-K | SEC EDGAR | -2.41% | +0.69% | |
| Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026 | Press release | ACCESS Newswire | -1.20% | +10.40% | |
| Form 10-Q Dermata Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.20% | +10.40% | |
| Form 8-K Dermata Therapeutics, For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -1.20% | +10.40% | |
| Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment | Press release | ACCESS Newswire | +0.34% | +3.54% | |
| Form 8-K Dermata Therapeutics, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.34% | +3.54% | |
| Form S-8 Dermata Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.01% | -5.60% | |
| Form EFFECT Dermata Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -3.03% | +1.51% | |
| Form 8-K Dermata Therapeutics, For: May 27 | SEC filing · Form 8-K | SEC EDGAR | +3.20% | +8.00% | |
| Form S-3/A Dermata Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -3.91% | |
| Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 | Press release | ACCESS Newswire | -0.81% | +0.00% | |
| Form 10-Q Dermata Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.81% | +0.00% | |
| Form 8-K Dermata Therapeutics, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -0.81% | +0.00% | |
| Form DEF 14A Dermata Therapeutics, For: Apr 17 | SEC filing · Form DEF | SEC EDGAR | -0.36% | -4.35% | |
| Form ARS Dermata Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.74% | -0.74% | |
| Form DEF 14A Dermata Therapeutics, For: Apr 17 | SEC filing · Form DEF | SEC EDGAR | +0.74% | -0.74% | |
| Form DEFA14A Dermata Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.74% | -0.74% | |
| Form PRE 14A Dermata Therapeutics, For: Apr 06 | SEC filing · Form PRE | SEC EDGAR | -0.79% | +3.70% | |
| Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System | Press release | ACCESS Newswire | -1.25% | +7.50% | |
| Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 | Press release | ACCESS Newswire | -2.21% | -13.23% | |
| Form 10-K Dermata Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.21% | -13.23% | |
| Form 8-K Dermata Therapeutics, For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -2.21% | -13.23% | |
| Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing | Press release | ACCESS Newswire | -3.03% | -3.79% | |
| Dermata Opens a New Chapter with the Release of Tome Skincare | Press release | ACCESS Newswire | +0.00% | +0.83% | |
| Form 8-K Dermata Therapeutics, For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | +2.63% | +2.46% | |
| Form 8-K Dermata Therapeutics, For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | +3.48% | +3.21% | |
| Form EFFECT Dermata Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.90% | -19.36% | |
| Form 8-K Dermata Therapeutics, For: Jan 27 | SEC filing · Form 8-K | SEC EDGAR | +1.06% | -8.51% | |
| Form S-3 Dermata Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +1.63% | -8.05% | |
| Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office | Press release | ACCESS Newswire | +0.47% | +2.36% | |
| Form D Dermata Therapeutics, | SEC filing · Form D | SEC EDGAR | +0.46% | -2.73% | |
| Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | ACCESS Newswire | +1.65% | -5.79% | |
| Form 8-K Dermata Therapeutics, For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | +1.65% | -5.79% | |
| Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | ACCESS Newswire | -0.36% | -5.58% | |
| A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity | Press release | ACCESS Newswire | -3.52% | -11.27% | |
| Form S-3 Dermata Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -1.46% | +8.03% | |
| Form 8-K Dermata Therapeutics, For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | -2.18% | -2.91% | |
| Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Press release | ACCESS Newswire | -7.03% | -9.27% | |
| Form 10-Q Dermata Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.03% | -9.27% | |
| Form 8-K Dermata Therapeutics, For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | -7.03% | -9.27% | |
| Form 8-K Dermata Therapeutics, For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | +7.47% | |
| Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office | Press release | ACCESS Newswire | +0.80% | -2.00% | |
| Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing | Press release | GlobeNewswire | +0.00% | +2.69% | |
| Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025 | Press release | ACCESS Newswire | -2.03% | -5.42% | |
| Form 8-K Dermata Therapeutics, For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | -2.03% | -5.42% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DRMA section they belong to.
Where else DRMA is measured.
DRMA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Dermata Therapeutics, Inc.'s median reaction calculated?
Every labeled DRMA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 227 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of DRMA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DRMA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.